Shionogi Plans $2.0 Billion Acquisition of IntraBio; Deal Has Not Closed
Key Facts
Shionogi’s proposed acquisition of IntraBio has not been confirmed as completed, despite its announced value of $2.0 billion. In an announcement on October 5, 2026, Shionogi said its U.S. subsidiary, Shionogi Inc., would buy all outstanding shares in IntraBio for an upfront payment to shareholders. The company set a planned closing window of November to December 2026, subject to closing conditions, regulatory approvals and waiting periods related to competition laws. In its disclosure on financing the deal on November 10, Shionogi described the acquisition as planned and did not announce its completion. Meanwhile, the company’s shares, listed under ticker 4507.t, closed at 3238 yen on November 16, according to EL7 data.
Shionogi says the proposed acquisition would add AQNEURSA and IntraBio’s rare-disease capabilities to its portfolio as it seeks to strengthen its business in the field. Chief Executive Isao Teshirogi said the plan reflects a “firm commitment to building a leading global rare-disease business.” The deal would combine an existing drug asset with development expertise in rare diseases, according to the company’s description. Shionogi did not link its share-price close on November 16 to completion of the deal in its disclosure. The available official announcement also places closing in a later period and makes it conditional on meeting closing requirements.
AQNEURSA is central to the proposed deal. Shionogi said it was approved by the U.S. Food and Drug Administration in September 2024 to treat neurological manifestations of Niemann-Pick disease type C, and then by the European Medicines Agency in January 2026 for the same use. The company added that the FDA approved it on September 18, 2026, to treat ataxia in patients with Ataxia-Telangiectasia. The FDA label says it is indicated for adult and pediatric patients with neurological manifestations of Niemann-Pick disease type C, as well as ataxia associated with Ataxia-Telangiectasia syndrome, who weigh at least 15 kilograms. Shionogi said an application to use AQNEURSA in adults and children with ataxia associated with Ataxia-Telangiectasia syndrome remains under review by the European agency. The drug’s regulatory path therefore includes existing approvals and an additional application under review, according to disclosures by the company and the regulator.
The value of IntraBio that Shionogi is seeking to acquire also extends to other development programs. The company said the target’s expertise would support its clinical rare-disease programs, including Pompe disease, Fragile X syndrome and Jordan syndrome, as well as early-stage programs for rare neurodegenerative diseases. IntraBio’s financial data published in the Japanese disclosure on the deal show consolidated revenue rising to $67.867 million in the fiscal year ended 2025, from $3.535 million the previous year. In contrast, the company posted a consolidated operating loss of $35.292 million in 2025, compared with a loss of $56.215 million in 2024. These figures provide financial context on the target company ahead of the proposed closing, alongside the drug portfolio and programs Shionogi says it would add. The deal remains subject to its announced conditions, so the figures and programs do not mean ownership has transferred.
To fund the deal, Shionogi announced on November 10 that it had borrowed ¥300 billion from Sumitomo Mitsui Banking Corporation through bridge financing. The company set October 29, 2027, as the repayment deadline and said it plans to refinance the loan with medium- to long-term financing before then. It said the financing’s impact on its consolidated results for the fiscal year ending March 31, 2027, is expected to be slight. The arrangement puts deal financing on a short-term footing pending the planned refinancing, while the acquisition itself remains subject to closing conditions, regulatory approvals and waiting periods. The latest available official announcement set a planned closing window of November to December 2026, without confirming that the deal had closed.